BioMarin Pharmaceutical Inc. Got It Done in the Second Quarter
BioMarin Pharmaceutical (NASDAQ: BMRN) turned in a second-quarter report on Wednesday that showed it continuing to grow sales of its current drugs, getting new drugs approved, and producing promising clinical trial data on its pipeline candidates. There isn't much else investors in biotechs can ask for.
Metric
Q2 2017
Source: Fool.com
BioMarin Pharmaceutical Inc. Stock
€76.94
-0.290%
With 27 Buy predictions and not a single Sell prediction BioMarin Pharmaceutical Inc. is an absolute favorite of our community.
As a result the target price of 102 € shows a positive potential of 32.57% compared to the current price of 76.94 € for BioMarin Pharmaceutical Inc..
